The vaccine manufacturer, Curevac has completed its private financing round. Overall, the company is working on a vaccine against the Coronavirus has $ 640 million, the equivalent of so 560 million euros collected, of which some of the investments were already previously known, according to the tübingen-based biotech company on Tuesday.
Ilka Kopplin
editor in the economy.
F. A. Z.
As a new Investor, the Emirate of Qatar is now the Qatar Investment Authority (QIA) was added. The QIA and a group of existing and new investors have become involved, according to Curevacs with the equivalent of around 110 million euros (126 million dollars). The exact proportion of the tübingen-based company is not quantified.
Known which on Monday published the participation of the British pharmaceutical company Glaxo-Smith-Kline (GSK) over approximately 150 million euros, which corresponded to a share of just under 10 percent, however, was already. Thus, Curevac has a rating of with now around 1.5 billion euros. As a few weeks earlier, the German state was entered via the Kreditanstalt für Wiederaufbau (KfW), with around 300 million euros, this corresponded to a share of around 23 percent and the company was thus valued at around EUR 1.3 billion. In the total sum of the announced round of financing, the German state participation is included already.
one of the existing investors SAP founder Hopp
had at the time, internal documents, according to well therefore a rapid state of entry-driven, because the tübingen sought in July in America to the stock exchange. Curevac has not commented on a possible IPO to date. In the spring there had been rumors that the American President Donald Trump have shown interest in the company from Tübingen.
among the previous investors Curevacs the founder of SAP, Dietmar Hopp, through his Investment company Dievini, the Bill&Melinda Gates Foundation and the private-public Alliance, Cepi committed to the fight against epidemics.
The Mainz competitor Biontech, is listed since last year at the American technology stock exchange Nasdaq, had recently gained as a new Investor, the Singaporean sovereign wealth Fund Tremasek for themselves, had also participated in a round of financing.
competitor Biontech published positive data
Curevac and Biontech to work both in a Corona-vaccination based on the mRNA-technology. This refers to messengers for the communication between the cells responsible. MRNA is considered to produce relatively quickly, however, a vaccination is, as yet, been never allowed this genbasierten technology.
